Defining High Risk Prostate Cancer-Where do we Set the Bar? A Translational Science Approach to Risk Stratification

Journal of Urology

Volumn 176, Issue 6 SUPPL., 2006, Pages

  Thompson, Ian M ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

prostate; prostate specific antigen; prostatic neoplasms; risk

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; DATA ANALYSIS; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; INTERSTITIAL RADIATION; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT;

DECISION MAKING; DISEASE PROGRESSION; HUMANS; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS;

EID: 33750469039     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.078     Document Type: Article

References (20)

1. Weir H.K., Thun M.J., Hankey B.F., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276
2. Middleton R.G., Thompson I.M., Austenfeld M.S., Cooner W.H., Correa R.J., Gibbons R.P., et al. Prostate Cancer Clinical Guideline Panel Summary report on the management of clinically localized prostate cancer. American Urological Association. J Urol 154 (1995) 2144
3. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Tomaszewski J.E., Kaplan I., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 280 (1998) 969
4. Thompson K.E., Hernandez J., Canby-Hagino E.D., Troyer D., and Thompson I.M. Prognostic features in men who died of prostate cancer. J Urol 174 (2005) 553
5. American Cancer Society. Cancer Facts and Figures, 2004. Atlanta: American Cancer Society, 2004. Available at http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf. Accessed October 24, 2005
6. Cao D., Hafez M., Berg K., Murphy K., and Epstein J.I. Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen?: a microsatellite analysis of specimen identity. Am J Surg Pathol 29 (2005) 467
7. Truskinovsky A.M., Sanderson H., and Epstein J.I. Characterization of minute adenocarcinomas of prostate at radical prostatectomy. Urology 64 (2004) 733
8. Bastian P.J., Mangold L.A., Epstein J.I., and Partin A.W. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101 (2004) 2001
9. Chan T.Y., Chan D.Y., Stutzman K.L., and Epstein J.I. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?. J Urol 166 (2001) 2181
10. Cheng L., Jones T.D., Pan C.X., Barbarin A., Eble J.N., and Koch M.O. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18 (2005) 1022
11. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
12. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66
13. Eastham J.A. Active surveillance for prostate cancer with selective delayed definitive therapy. Clin Prostate Cancer 4 (2005) 45
14. Klotz L.H. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. Can J Urol, suppl. 12 (2005) 53
15. Choo R., Klotz L., Danjoux C., Morton G.C., DeBoer G., Szumacher E., et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histologic and/or clinical progression. J Urol 167 (2002) 1664
16. Greene K.L., Meng M.V., Elkin E.P., Cooperberg M.R., Pasta D.J., Kattan M.W., et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol 171 (2004) 2255
17. Partin A.W., Kattan M.W., Subong M.S., et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 277 (1999) 1445
18. Cooperberg M.R., Mehta S.S., Lubeck D.P., Meng M.V., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and treatment patterns (data from CaPSURE). J Urol, suppl. 169 (2003) 459 abstract 1723
19. Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172 (2004) S48
20. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433